Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
8(53%)
Results Posted
14%(1 trials)

Phase Distribution

Ph phase_2
3
20%
Ph phase_1
4
27%
Ph phase_3
8
53%

Phase Distribution

4

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
4(26.7%)
Phase 2Efficacy & side effects
3(20.0%)
Phase 3Large-scale testing
8(53.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

15

all time

Status Distribution
Active(8)
Completed(7)

Detailed Status

Completed7
Active, not recruiting4
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
15
Active
8
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (26.7%)
Phase 23 (20.0%)
Phase 38 (53.3%)

Trials by Status

active_not_recruiting427%
completed747%
recruiting427%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT06855498Phase 3

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Recruiting
NCT05851443Phase 2

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Recruiting
NCT06516965Phase 3

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Active Not Recruiting
NCT06516952Phase 3

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Recruiting
NCT06113471Phase 3

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Active Not Recruiting
NCT06212999Phase 3

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Active Not Recruiting
NCT06113445Phase 3

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Active Not Recruiting
NCT07213973Phase 2

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
NCT05936567Phase 2

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Completed
NCT05620823Phase 3

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Completed
NCT05620836Phase 3

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed
NCT06416800Phase 1

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Completed
NCT06505265Phase 1

A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

Completed
NCT06441318Phase 1

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

Completed
NCT06380205Phase 1

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15